DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data that indicate KRYSTEXXA (pegloticase) injection with weekly oral methotrexate effectively treats uncontrolled ...
The FDA approved pegloticase (Krystexxa) injection coadministered with methotrexate, Horizon Therapeutics announced Friday. Pegloticase is currently the only FDA-approved medication used to reduce ...
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today topline results from its MIRROR open-label study in which methotrexate with KRYSTEXXA® (pegloticase injection) provided ...
The MarketWatch News Department was not involved in the creation of this content. MONTREAL, March 15, 2024 /CNW/ - Pharmascience Canada is proud to announce the launch of pms- METHOTREXATE INJECTION ...
DUBLIN--(BUSINESS WIRE)-- Horizon Therapeutics plc (Nasdaq: HZNP) today announced the publication of the long-term data from the MIRROR randomized controlled clinical trial of KRYSTEXXA® (pegloticase) ...
TOKYO, Feb 16, 2024 - (JCN Newswire) - - Eisai Co., Ltd. and nippon medac Co., Ltd., a subsidiary of medac Gesellschaft fur klinische Spezialpraparate mbH announced that they have obtained ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback